Sangamo Therapeutics discusses Q4 2024 financial results

Sangamo Therapeutics, Inc. held its fourth-quarter earnings call on March 17, 2025. This event included key company executives, such as CEO Sandy Macrae and CFO Prathyusha Duraibabu. During the call, the company discussed its financial performance for the past year. Sangamo emphasized its focus on research and development, aiming to advance its therapeutic products. The executives highlighted their plans for future collaborations and the potential updates on clinical trials. The call featured a reminder that some statements made are forward-looking. This means they involve predictions about the company's future and outcomes, which could change due to various risks. Sangamo also addressed its financial situation, including its plans to secure further funding to maintain operations. Detailed slides related to the presentation are available on the company's website.